This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Haase Investments Ug. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Petra Seemann: Innovator in Bone Morphogenetic Protein Research
Introduction
Petra Seemann is a distinguished inventor based in Berlin, Germany. She has made significant contributions to the field of biomedical research, particularly in the area of bone morphogenetic proteins. Her innovative work has led to the development of novel peptide variants that have potential applications in medical therapies.
Latest Patents
Petra Seemann holds a patent for "Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity." This invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1. The patent is characterized by at least two amino acid substitutions, with the first substitution occurring at specific positions of SEQ ID No. 1, which enhances its therapeutic potential.
Career Highlights
Throughout her career, Petra has worked with notable companies such as Haase Investments UG and Selenomed GmbH. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Petra has collaborated with esteemed colleagues, including Stefan Mundlos and Carsten Reissner. These partnerships have further enriched her research and expanded the impact of her innovations.
Conclusion
Petra Seemann is a remarkable inventor whose work in bone morphogenetic proteins has the potential to revolutionize medical treatments. Her dedication to research and innovation continues to inspire advancements in the field.